ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1147

TGFß1 Blocks Chondrocyte Hypertrophy and Increases Cell Viability in Cultured Cartilage Explants but Does Not Protect Against Proteoglycan Loss

Arjan van Caam, Wojciech Madej, Henk van Beuningen, Esmeralda Blaney Davidson and Peter van der Kraan, Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cartilage, chondrocytes, Collagen, proteoglycans and transforming growth factor

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

In osteoarthritis, cartilage degradation is partly due to chondrocytes gaining a hypertrophy-like phenotype. TGFβ1 is considered to be a protective factor for articular cartilage by blocking this hypertrophy and by inducing production of matrix molecules like proteoglycans (e.g. aggrecan). However, these functions of TGFβ1 have been identified using very young cartilage whereas TGFβ1-signaling is known to change upon maturation (ageing). Therefore, we investigated in healthy mature cartilage the effect of TGFβ1 on chondrocyte phenotype, viability and total amount of glycosaminoglycans (GAGs, as measure for proteoglycans) in long term ex vivo culture.

Methods: Articular cartilage explants were isolated from the metacarpophalangeal joint of healthy 5 yr old adult cows. Subsequently, explants were cultured in DMEM/F12 alone or supplemented with either 10% Fetal Calf Serum (FCS), rhTGFβ1 or rhIGF1 for the duration of 2 weeks. To investigate via which TGFβ1 receptor, ALK1 or ALK5, the observed TGFβ1 effects run, the ALK5-kinase inhibitor SB-505124 (5 μM) was used. Sulfated-GAGs were measured using dimethylmethylene blue (DMB). Cellular viability was measured with the use of XTT. To correct for the amount of cells, total DNA content of explants was measured using PicoGreen. Furthermore, gene expression of chondrocyte hypertrophy markers was measured using qPCR.

Results: Two weeks of ex vivo explant culture resulted in GAG loss; total GAG content was reduced from approximately 4% of wet weight in freshly isolated explants to 1% of wet weight in cultured explants. Addition of 10% FCS fully prevented this GAG loss. In contrast, TGFβ1 (10 ng/ml) was unable to inhibit GAG loss. Replacement of 10% FCS with 20 ng/ml of IGF1 also prevented GAG loss, but surprisingly, when IGF1 was combined with TGFβ1, TGFβ1 inhibited the positive effect of IGF1 on total GAG content. Compared to freshly isolated samples, expression of the chondrocyte-hypertrophy markers Col10a1 and Mmp13 was profoundly upregulated in explants cultured for 2 weeks. The addition of 10% FCS to the medium did not inhibit the upregulation of these genes, and even induced expression of Alkaline phosphatase (Alpl), another marker of chondrocyte hypertrophy. In contrast, addition of TGFβ1 (1 ng/ml or 10 ng/ml) fully blocked induction of Col10a1 and Mmp13 expression, and lowered expression of Alpl 4-fold. Additionally, TGFβ1 induced Col2a1 expression 16-fold. TGFβ1 also enhanced chondrocyte viability, because after 2 weeks, mitochondrial activity was 50% higher in TGFβ1 treated samples compared to 10% FCS treated samples. All these effects of TGFβ1 were blocked by 5 μM of the ALK5-kinase inhibitor SB-505124. 

Conclusion:

Based on our results, we conclude that in adult cartilage TGFβ1 is a potent inhibitor of chondrocyte hypertrophy and that this inhibition runs via ALK5. Additionally, TGFβ1 profoundly induced Col2a1 production, and maintained chondrocyte viability in long term culture. In contrast, TGFβ1 was not able to counteract GAG depletion over time and even inhibited the beneficial effect of IGF1 on total GAG-content in cartilage, demonstrating that TGFβ1 does not positively regulate GAG content in adult cartilage.


Disclosure: A. van Caam, None; W. Madej, None; H. van Beuningen, None; E. Blaney Davidson, None; P. van der Kraan, None.

To cite this abstract in AMA style:

van Caam A, Madej W, van Beuningen H, Blaney Davidson E, van der Kraan P. TGFß1 Blocks Chondrocyte Hypertrophy and Increases Cell Viability in Cultured Cartilage Explants but Does Not Protect Against Proteoglycan Loss [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/tgfs1-blocks-chondrocyte-hypertrophy-and-increases-cell-viability-in-cultured-cartilage-explants-but-does-not-protect-against-proteoglycan-loss/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tgfs1-blocks-chondrocyte-hypertrophy-and-increases-cell-viability-in-cultured-cartilage-explants-but-does-not-protect-against-proteoglycan-loss/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology